공시 • Apr 30
Cipher Pharmaceuticals Inc. to Report Q1, 2026 Results on May 07, 2026 Cipher Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 공시 • Apr 21
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026 Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 18, 2026. Location: ontario, toronto Canada 공시 • Mar 05
Cipher Pharmaceuticals Inc. to Report Q4, 2025 Results on Mar 12, 2026 Cipher Pharmaceuticals Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Mar 12, 2026 공시 • Jan 29
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™? (Spinosad) Cipher Pharmaceuticals Inc. announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™? (Spinosad), for the treatment of head lice and scabies. Natroba™? (Spinosad) is widely recognized as one of the most effective treatments for the two parasitic indications of head lice and sc babies in the U.S. It is superior to the widely used permethrin 1% for treating head lice and is the only treatment in the U.S. that meets the FDA's criteria for a " complete cure" (elimination of all signs and symptoms) in eradicating sc babies infestations with a single application. Cipher acquired Natroba™? (spinosad) in July 2024, and since acquisition has marketed and distributed the product in the United States ("U.S.) market, through its commercial infrastructure. 공시 • Oct 30
Cipher Pharmaceuticals Inc. to Report Q3, 2025 Results on Nov 06, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 공시 • Aug 28
Cipher Pharmaceuticals Inc. Announces the Passing of Board Director and Chairman of Audit Committee Harold M. Wolkin Cipher Pharmaceuticals Inc. announced the passing of Harold M. Wolkin, a valued member of the Company's Board of Directors and Chairman of the Audit Committee. Mr. Wolkin was a very active member of the Board and his deep understanding of the capital markets and unwavering commitment to the Company's growth and governance were tremendously valuable to the Company. During his tenure, he played a vital role in guiding strategic initiatives, supporting management, and representing the Company and its shareholders with integrity. Harold was a very well-known and highly respective member of the Canadian capital markets community and he will truly be missed by those that knew him. 공시 • Jul 29
Cipher Pharmaceuticals Inc. to Report Q2, 2025 Results on Aug 07, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q2, 2025 results at 4:00 PM, US Eastern Standard Time on Aug 07, 2025 공시 • May 03
Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on May 08, 2025 공시 • Apr 09
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025 Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025. Location: ontario, toronto Canada 공시 • Mar 12
Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025 Cipher Pharmaceuticals Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Mar 18, 2025 공시 • Nov 04
Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Cipher Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024 공시 • Oct 08
Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer Cipher Pharmaceuticals Inc. announced the appointment of Hamed Ghanei as Chief Business Officer. Dr. Ghanei has over 15 years of experience in specialty pharmaceuticals, venture funds, and healthcare investment banking. Throughout his career, he has led the evaluation of over 500 licensing and M&A opportunities and has been involved in five commercial product launches. He has successfully negotiated over 20 transactions with total value exceeding $1 billion. Dr. Ghanei holds a B.Sc. from the University of Waterloo, a M.Sc. in Microbiology and Biochemistry from the University of Guelph, and a Ph.D. in Medical Biophysics from the University of Toronto. 공시 • Aug 02
Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Cipher Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Aug 08, 2024 공시 • Apr 09
Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024 Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024. 공시 • Mar 09
Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024 Cipher Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Mar 14, 2024 공시 • Oct 28
Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023 Cipher Pharmaceuticals Inc. announced that they will report Q3, 2023 results on Nov 09, 2023 공시 • Sep 06
Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares. Cipher Pharmaceuticals Inc. (TSX:CPH) announces a share repurchase program. Under the substantial issuer bid, the company will repurchase up to CAD 6 million worth of its outstanding shares. The shares will be tendered at a price of not less than CAD 3.95 per share and not more than CAD 4.75 per share. The company plans to fund the offer from available cash on hand. The shares purchased under the offer will be cancelled. If the aggregate cost to purchase the tendered shares exceeds $6 million, the company will accept such shares on a pro-rata basis after giving effect to “odd lot” tenders, which will not be subject to pro-ration. The bid will expire on October 11, 2023, unless extended or withdrawn. 공시 • Jul 29
Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023 Cipher Pharmaceuticals Inc. announced that they will report Q2, 2023 results on Aug 10, 2023 공시 • May 05
Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023 Cipher Pharmaceuticals Inc. announced that they will report Q1, 2023 results on May 11, 2023 공시 • Feb 14
Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023 On February 10, 2022, the Board of Directors of Cipher Pharmaceuticals Inc. declared a quarterly dividend of $0.0.01875 per share to shareholders of record on February 21, 2023, payable on or about February 28, 2023.